SPECT MPI

DRUG3 trials

Sponsors

Gilead Sciences, GE Healthcare, Centre Hospitalier Régional d'Orléans

Conditions

Amyloid CardiomyopathyCoronary Artery Disease (CAD)Myocardial IschemiaMyocardial Perfusion Imaging

Phase 3

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

CompletedNCT03354273

GE HealthcareCoronary Artery Disease (CAD)

Start: 2018-06-05End: 2022-05-05Updated: 2023-07-12

Phase 4

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

CompletedNCT01221272

Gilead SciencesMyocardial Ischemia, Myocardial Perfusion Imaging

Start: 2010-09-30End: 2012-09-30Updated: 2014-09-03

Unknown Phase

Amyloidosis TTR Flow Reserve Evaluation

Active, not recruitingNCT05103943

Centre Hospitalier Régional d'OrléansAmyloid Cardiomyopathy

Start: 2022-02-24End: 2026-12-11Target: 50Updated: 2025-12-23

Related Papers

Comparison, Agreement, and Significance Cutoffs of <sup>18</sup>F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages.

2025-11-031 citations

Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease.

2023-10-0161 citations

A study protocol for an observational cohort investigating cardiac transthyretin amyloidosis flow reserve before and after Tafamidis treatment: The AMYTRE study

Frontiers in Medicine2022-08-232 citations

Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging.

2021-01-3113 citations